medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2012, Number 3

<< Back Next >>

Ann Hepatol 2012; 11 (3)

Treatment of hyperferritinemia

Beaton MD, Adams PC

Language: English
References: 41
Page: 294-300
PDF size: 89.53 Kb.


ABSTRACT

Elevated serum ferritin, or hyperferritinemia, is a common finding on routine bloodwork and often prompts referral for further evaluation. In the following review, we outline the various causes of hyperferritinemia and point out that, in the majority of cases, this does not represent true iron overload. Despite much research interest in this area, the precise mechanism of hyperferritinemia and its impact on disease severity in various clinical conditions continues to be debated. While some research suggests that iron reduction in cases of hyperferritinemia is of benefit, the decision to treat such patients should be individualized, and may be influenced by the presence of other features of iron overload.


REFERENCES

  1. Ogilvie C, Fitzsimons K, Fitzsimons E. Serum ferritin values in primary care: are high values overlooked? J Clin Pathol 2010; 63: 1124-6.

  2. Zanella A, Gridelli L, Berzuini A, Colotti MT, Mozzi F, Milani S, Sirchia G. Sensitivity and predictive value of serum ferritin and free erythrocyte protoporphyrin for iron deficiency. J Lab Clin Med 1989; 113(1): 73.

  3. Kushner I. The phenomenon of the acute phase response. Ann N Y Acad Sci 1982; 389: 39.

  4. Adams PC, Reboussin DM, Barton JC, McLaren CE, Eckfeldt JH, McLaren GD, Dawkins FW, et al. Hemochromatosis and iron-overload screening in a racially diverse population. N Engl J Med 2005; 352: 1769-78.

  5. Wong K, Adams PC. The diversity of liver diseases among outpatient referrals for elevated serum ferritin. Can J Gastroenterol 2006; 20(7): 467-470.

  6. Adams PC, Reboussin DM, Leiendecker-Foster C, Moses G, McLaren GD, McLaren CE, Dawkins FW, et al. Comparison of the unsaturated iron binding capacity with transferrin saturation as a screening test to detect C282Y homozygotes for hemochromatosis in 101,168 participants in the HEIRS study. Clin Chem 2005; 51: 1048-51.

  7. Adams PC, Reboussin DM, Press RD, Barton JC, Acton RT, Moses GC, Leiendecker-Foster C, et al. Biological variation of transferrin saturation and unsaturated iron-binding capacity. Am J Med 2007; 120(11): 999.e1-7.

  8. Powell LW, Alpert E, Isselbacher KJ, Drysdale JW. Human isoferritins: organ specific and apoferritin distribution. Br J Haematol 1975; 30(1): 47-55.

  9. ArosioP, Ingrassia R, Cavadini P. Ferritins: a family of molecules for iron storage, antioxidation and more. Biochim Biophys Acta 2009; 1790(7): 589-99.

  10. Herbert V, Jayatilleke E, Shaw S, et al. Serum ferritin iron, a new test, measures human body iron stores unconfounded by inflammation. Stem Cells 1997; 15(4): 291-6.

  11. Adams PC, Beaton MD. Transferrin saturation as a predictor of hepatic iron overload. Liver Int 2011; 31(2): 272-3.

  12. Pietrangelo A. Hereditary hemochromatosis: a new look at an old disease. N Eng J Med 2004; 350: 2383-97.

  13. Campbell MS, Reddy KR. Review article: the evolving role of liver biopsy. Aliment Pharmacol Ther 2004; 20: 249-59.

  14. Merriman RB, Ferrell LD, Patti MG, Weston SR, Pabst MS, Aouizerat BE, Bass NM. Correlation of paired liver biopsies in morbidly obese patients with suspected nonalcoholic fatty liver disease. Hepatology 2006; 44(4): 874-80.

  15. Sirlin CB, Reeder SB. Magnetic resonance imaging quantification of liver iron. Magn Reson Imaging Clin N Am 2010; 18: 359-81.

  16. Beddy P, McCann J, Ahern M. MRI assessment of changes in liver iron deposition post-venesection. Eur J Radiol 2011; 80(2): 204-7.

  17. Yoo KD, Ko SH, Park JE, Ahn YB, Yim HW, Lee WC, Park YM. High serum ferritin levels are associated with metabolic risk factors in non-obese Korean young adults: Korean National Health and Nutrition Examination Survey (KNHANES) IV. Clin Endocrinol (Oxf) 2011 [Epub ahead of print].

  18. Lee BK, Kim Y, Kim YI. Association of serum ferritin with metabolic syndrome and diabetes mellitus in the South Korean general population according to the Korean National Health Nutrition Examination Survey 2008. Metabolism 2011; 60(10): 1416-24.

  19. Beaton MD, Adams PC. Prognostic factors and survival in patients with hereditary hemochromatosis and cirrhosis. Can J Gastroenterol 2006; 20(4): 257-60.

  20. Turlin B, Juguet F, Moirand R, Le Quileuc D, Loreal O, Campion JP, Launois B, et al. Increased liver iron stores in patients with hepatocellular carcinoma developed in a noncirrhotic liver. Hepatology 1995; 22: 446-50.

  21. Mainous AG, Diaz VA. Relation of serum ferritin level to cardiovascular fitness among young men. Am J Cardiol 2009; 103(1): 115-8.

  22. Menke A, Fernandez-Real JM, Munter P, Guallar E. The association of biomarkers of iron status with peripheral arterial disease in US adults. BMC Cardiovasc Disord 2009; 3(9): 34.

  23. Depalma RG, Hayes VW, Chow BK, Shamayeva G, May PE, Zacharski LR. Ferritin levels, inflammatory biomarkers, and mortality in peripheral arterial disease: a substudy of the Iron (Fe) and Atherosclerosis Study (FeAST) Trial. J Vasc Surg 2010; 51(6): 1498-503.

  24. Jiang R, Manson JE, Meigs JB, Ma J, Rifai N, Hu FB. Body iron stores in relation to risk of type 2 diabetes in apparently healthy women. JAMA 2004; 129(6): 711-7.

  25. Jehn M, Clark JM, Guallar E. Serum ferritin and risk of the metabolic syndrome in U.S. Adults. Diabetes Care 2004; 27(10): 2422-8.

  26. Kowdley KV, Belt P, Wilson LA, Yeh MA, Neuschwander-Tetri BA, Chalasani N, Sanyal AJ, et al. Elevated serum ferritin is an independent predictor of histologic severity and advanced fibrosis among patients with nonalcoholic fatty liver disease. Hepatology 2012; 55:77-85.

  27. Bozzini C, Girelli D, Olivieri O, Martinelli N, Bassi A, De Matteis G. Prevalence of body iron excess in the metabolic syndrome. Diabetes Care 2005; 28: 2061-3.

  28. Jiang R, Manson JE, Meigs JB, Ma J, Rifai N, Gu FB. Body iron stores in relation to risk of type 2 diabetes in apparently healthy women. JAMA 2004; 291: 711-7.

  29. Ramm GA, Ruddell RG. Hepatotoxicity of iron overload: mechanisms of iron-induced hepatic fibrogenesis. Semin Liv Dis 2005; 25(4): 433-49.

  30. Sakaida I, Okita K. The role of oxidative stress in NASH and fatty liver model. Hep Res 2005; 33: 128-131.

  31. Lee KS, Buck M, Houglum K, Chojkier M. Activation of hepatic stellate cells by TGF alpha and collagen type 1 is mediated by oxidative stress through c-myb expression. J Clin Invest 1995; 96: 2461-8.

  32. Zacharski LR, Chow BK, Howes, Shamayeva G, Baron JA, Dalman RL, Malenka DJ, et al. Reduction of iron stores and cardiovascular outcomes in patients with peripheral arterial disease: a randomized controlled trial. JAMA 2007; 297(6): 603-10.

  33. Zacharski LR, Shamayeva G, Chow BK. Effect of controlled reduction of body iron stores on clinical outcomes in peripheral arterial disease. Am Heart J 2011; 162(5): 949- 957.e1.

  34. Lambrecht RW, Sterling RK, Naishadham D, Stoddard AM, Rogers T, Morishima C, Morgan TR, Bonkovsky HL; HALT-C Trial Group. Iron levels in hepatocytes and portal tract cells predict progression and outcomes of patients with advanced chronic hepatitis C. Gastroenterol 2011; 140(5): 1490-500.

  35. Kato J, Miyanishi K, Kobune M, Nakamura T, Takada K, Takimoto R. Long-term phlebotomy with low-iron diet therapy lowers risk of development of hepatocellular carcinoma from chronic hepatitis C. J Gastroenterol 2007; 42: 830-6.

  36. Starley BQ, Calcagno CJ, Harrison SA. Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection. Hepatology 2010; 51(5): 1820-32.

  37. Mascitelli L, Goldstein MR. Metabolic syndrome and liver cancer: is excess iron the link? Hepatol 2011; 54(4): 1487.

  38. Houglum K, Ramm GA, Crawford DHG, Witzum JL, Powell LW, Choikier M. Excess iron induces hepatic oxidative stress and transforming growth factor β1 in genetic hemochromatosis. Hepatology 1997; 26(3): 607-10.

  39. Valenti L, Fracanzani AL, Dongiovanni P, Bugianesi E, Marchesini G, Manzini P, Vanni E, et al. Iron depletion by phlebotomy improves insulin resistance in patients with non-alcoholic fatty liver disease and hyperferritinemia: evidence from a case-control study. Am J Gastroenterol 2007; 102: 1251-8.

  40. Valenti L, Fracanzani AL, Fargion S. Effect of iron depletion in patients with nonalcoholic fatty liver disease without carbohydrate intolerance. Gastroenterology 2003; 124: 866-7.

  41. Valenti L, Moscatiello S, Vanni E, Fracanzani AL, Bugianesi E, Fargion S, Marchesini G. Venesection for non-alcoholic fatty liver disease unresponsive to lifestyle counseling-a propensity score-adjusted obvservational study. QJM 2011; 104(2): 141-9.




2020     |     www.medigraphic.com